Publications by authors named "J A Pongracic"
Background: Omalizumab (XOLAIR®)-assisted multi-food oral immunotherapy (mOIT) has been shown to safely, effectively, and rapidly desensitize patients with multiple food allergies. In our clinical trial (NCT02626611) on omalizumab-assisted mOIT, different desensitization outcomes (success or failure of desensitization) were observed following a period of either continued or discontinued mOIT. However, the association between the immunological changes induced by omalizumab-assisted mOIT and desensitization outcomes has not yet been fully elucidated.
View Article and Find Full Text PDFArticle Synopsis
- IgE-mediated food allergies can affect anyone, with symptoms developing quickly after eating allergens but lacking a consistent presentation for individuals.
- Common symptoms include skin and gastrointestinal reactions, but not all allergic responses show these signs; thus, the absence of skin symptoms does not rule out anaphylaxis.
- These allergies can range from mild to severe, with rare cases resulting in death, and factors like alcohol consumption and physical exertion can worsen reactions.
Article Synopsis
- - The study aimed to assess whether one year of subcutaneous immunotherapy (SCIT) would improve nasal responses to cockroach allergens in urban children with asthma who are sensitive to these allergens.
- - Results indicated that there was no significant improvement in total nasal symptom scores (TNSS) after SCIT compared to a placebo; however, SCIT did result in decreased skin reaction size and increased specific antibody production against the allergen.
- - Overall, while SCIT showed systemic effects by affecting immune responses, it did not change nasal symptoms or transcriptomic responses during allergen exposure.
Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities.
J Allergy Clin Immunol Glob
February 2023
Background: Co-occurring atopic conditions are common in children with peanut allergy. As such, it is important to examine the safety and efficacy of epicutaneous immunotherapy with Viaskin Peanut 250 μg patch (VP250) in peanut-allergic children with these conditions.
Objective: We sought to compare efficacy and safety of VP250 versus placebo in peanut-allergic children with/without ongoing atopic conditions at baseline, including asthma, atopic dermatitis/eczema, or concomitant food allergy.
Rhinoviruses (RVs) can cause severe wheezing illnesses in young children and patients with asthma. Vaccine development has been hampered by the multitude of RV types with little information about cross-neutralization. We previously showed that neutralizing antibody (nAb) responses to RV-C are detected twofold to threefold more often than those to RV-A throughout childhood.
View Article and Find Full Text PDF